Hemab Therapeutics
Created in 2019
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
5,498Activities
Technologies
Entity types
Location
Ole Maaløes Vej 3, 2200 København, Denmark
København
Denmark
Employees
Scale: 11-50
Estimated: 54
Engaged catalyst
2
0 0Added in Motherbase
2 years ago
Value proposition
The next generation of therapeutics for bleeding and thrombotic disorders
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders. Learn more at hemab.com.
Biotech
Hemab - bleeding disorder company
Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
https://hemab.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 J.P. Morgan Bank | J.P. Morgan Bank | Other 31 Dec 2024 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 31 Jan 2023 | | |